Business Description
Cinclus Pharma Holding AB
ISIN : SE0020388577
Total Employee Number:
17Compare
Compare
Traded in other countries / regions
CINPHA.SwedenJ8P.Germany IPO Date
2024-06-21Description
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.99 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.12 | |||||
Beneish M-Score | 123.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 71.6 | |||||
3-Year EBITDA Growth Rate | 9.9 | |||||
3-Year EPS without NRI Growth Rate | 11.8 | |||||
3-Year FCF Growth Rate | 28.4 | |||||
3-Year Book Growth Rate | 42.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -25.92 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.45 | |||||
9-Day RSI | 47 | |||||
14-Day RSI | 43.08 | |||||
3-1 Month Momentum % | -26.06 | |||||
6-1 Month Momentum % | -40.74 | |||||
12-1 Month Momentum % | -23.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.74 | |||||
Days Sales Outstanding | 32.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -3.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -359.8 | |||||
Net Margin % | -354.14 | |||||
EBITDA Margin % | -355.65 | |||||
FCF Margin % | -193.35 | |||||
OCF Margin % | -193.32 | |||||
ROE % | -57.93 | |||||
ROA % | -42.33 | |||||
ROIC % | -287.78 | |||||
3-Year ROIIC % | 16.91 | |||||
ROC (Joel Greenblatt) % | -4151.73 | |||||
ROCE % | -52.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.52 | |||||
PB Ratio | 1.81 | |||||
Price-to-Tangible-Book | 1.86 | |||||
EV-to-EBIT | -0.49 | |||||
EV-to-EBITDA | -0.5 | |||||
EV-to-Revenue | 1.76 | |||||
EV-to-FCF | -0.76 | |||||
| Price-to-Net-Current-Asset-Value | 1.9 | |||||
| Price-to-Net-Cash | 2.1 | |||||
Earnings Yield (Greenblatt) % | -204.95 | |||||
FCF Yield % | -23.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cinclus Pharma Holding AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.167 | ||
| EPS (TTM) (€) | -0.47 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 39.25 | ||
| 14-Day RSI | 43.08 | ||
| 14-Day ATR (€) | 0.017442 | ||
| 20-Day SMA (€) | 1.0076 | ||
| 12-1 Month Momentum % | -23.13 | ||
| 52-Week Range (€) | 0.948 - 1.792 | ||
| Shares Outstanding (Mil) | 46.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cinclus Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cinclus Pharma Holding AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 42 days | ||
| General meeting for 2026 | 2026-05-21 16:00 | 1.04 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 10:00 | 1.10 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 08:00 | 1.10 (+0.00%) | ||
| Annual report for 2025 | 2026-04-16 | 1.47 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 1.57 (+0.13%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-20 10:00 | 1.54 (+0.00%) |
Show
Entries
Cinclus Pharma Holding AB Frequently Asked Questions
What is Cinclus Pharma Holding AB(FRA:J8P)'s stock price today?
The current price of FRA:J8P is €0.99. The 52 week high of FRA:J8P is €1.79 and 52 week low is €0.95.
When is next earnings date of Cinclus Pharma Holding AB(FRA:J8P)?
The next earnings date of Cinclus Pharma Holding AB(FRA:J8P) is 2026-08-19.
Does Cinclus Pharma Holding AB(FRA:J8P) pay dividends? If so, how much?
Cinclus Pharma Holding AB(FRA:J8P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cinclus Pharma Holding AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers